Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CFB | P00751 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460783 | 1.00 | POLB (0.43) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL14067026 | 0.93 | — | — | |
| SCHEMBL2268870 | 0.93 | — | — | |
| SCHEMBL10867079 | 0.86 | SPHK2 (0.45) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL6992282 | 0.82 | MAPK1 (0.43) | ALDH1A1TERTTDP1KMT2AMEN1 | |
| SCHEMBL14155734 | 0.82 | ALDH1A1 (0.45) | POLBL3MBTL1ALDH1A1CFBSPHK2 | |
| SCHEMBL8977472 | 0.82 | ALDH1A1 (0.45) | POLBL3MBTL1ALDH1A1CFBSPHK2 | |
| SCHEMBL3426506 | 0.82 | SPHK2 (0.43) | POLBL3MBTL1ALDH1A1CFBTERT | |
| SCHEMBL6436481 | 0.82 | ALDH1A1 (0.45) | POLBL3MBTL1ALDH1A1CFBSPHK2 | |
| SCHEMBL9521804 | 0.80 | GBA1 (0.44) | POLBL3MBTL1ALDH1A1CFBTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334435-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | ABBVIE INC. | 2018-11-22 | — | — | US | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-0274929-A1 | Pyrrole derivatives, their preparation and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | POLB 1580/4885L3MBTL1 1744/4885ALDH1A1 1849/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | POLB 3297/4885L3MBTL1 653/4885ALDH1A1 1382/4885 |
| US-20180334435-A1 | 6-HETEROARYLOXY- OR 6-ARYLOXY-QUINOLINE-2-CARBOXAMIDES AND METHOD OF USE | SCN8A, SCN7A, SCN2A | POLB 4103/4885L3MBTL1 2597/4885ALDH1A1 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.